Carboxylated Psilocybin Derivatives and Methods of Using (US12605361B2)

USPTO granted patent US12605361B2 to Enveric Biosciences Canada Inc. for novel carboxylated psilocybin derivative compounds and pharmaceutical and recreational drug formulations containing the same. The compounds may be produced by reacting a reactant psilocybin derivative with a carboxyl or carboxylic acid derivative containing compound. The patent contains 18 claims and covers CPC classifications including A61K 31/404, A61P 25/18, and C07D 209/16.

Competitors developing psilocybin-based therapeutics or recreational drug formulations should conduct freedom-to-operate analyses to assess potential infringement risks. The patent does not create reporting or compliance obligations for third parties but establishes enforceable exclusive rights that could limit competitive market entry in the covered compound space.